ChiCTR2600121488 版本V1.1 版本创建时间2026/05/13 17:42:54 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600121488 

最近更新日期:

Date of Last Refreshed on:

2026-03-31 14:27:10 

注册时间:

Date of Registration:

2026-03-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

特瑞普利单抗治疗中国晚期实体肿瘤患者的真实世界研究

Public title:

A real-world study of toripalimab in the treatment of advanced solid tumor patients in China

注册题目简写:

English Acronym:

研究课题的正式科学名称:

特瑞普利单抗治疗中国晚期实体肿瘤患者的真实世界研究

Scientific title:

A real-world study of toripalimab in the treatment of advanced solid tumor patients in China

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

成瑜 

研究负责人:

成瑜 

Applicant:

Cheng Yu 

Study leader:

Cheng Yu 

申请注册联系人电话:

Applicant telephone:

+86 13105359789

研究负责人电话:

Study leader's
telephone:

+86 535 6691999

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

cy13105359789@163.com

研究负责人电子邮件:

Study leader's E-mail:

Liubaodong123@yeah.net

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

烟台芝罘区毓璜顶东路20号

研究负责人通讯地址:

烟台芝罘区毓璜顶东路20号

Applicant address:

No. 20, Yuhuangding East Road, Zhifu District, Yantai, Shandong, China

Study leader's address:

No. 20, Yuhuangding East Road, Zhifu District, Yantai, Shandong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

烟台毓璜顶医院

Applicant's institution:

Yantai Yuhuangding Hospital

研究负责人所在单位:

烟台毓璜顶医院

Affiliation of the Leader:

Yantai Yuhuangding Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

YYYIRB-IIT[2026]054

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

烟台毓璜顶医院临床研究伦理委员会

Name of the ethic committee:

Yantai Yuhuangding Hospital Clinical Research Institutional Review Board

伦理委员会批准日期:

Date of approved by ethic committee:

2026-03-23 00:00:00

伦理委员会联系人:

李康琪

Contact Name of the ethic committee:

Li Kangqi

伦理委员会联系地址:

烟台芝罘区毓璜顶东路20号

Contact Address of the ethic committee:

No. 20, Yuhuangding East Road, Zhifu District, Yantai, Shandong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 535 6691999

伦理委员会联系人邮箱:

Contact email of the ethic committee:

likangqiyt@163.com

研究实施负责(组长)单位:

烟台毓璜顶医院

Primary sponsor:

Yantai Yuhuangding Hospital

研究实施负责(组长)单位地址:

烟台芝罘区毓璜顶东路20号

Primary sponsor's address:

No. 20, Yuhuangding East Road, Zhifu District, Yantai, Shandong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东省

市(区县):

Country:

China

Province:

Shandong

City:

单位(医院):

烟台毓璜顶医院

具体地址:

烟台芝罘区毓璜顶东路20号

Institution
hospital:

Yantai Yuhuangding Hospital

Address:

No. 20, Yuhuangding East Road, Zhifu District, Yantai, Shandong, China

经费或物资来源:

Source(s) of funding:

None

研究疾病:

驱动基因阴性非小细胞肺癌,尿路上皮癌,食管癌,鼻咽癌,黑色素瘤,肾细胞癌,小细胞肺癌、三阴乳腺癌、肝细胞癌,肾细胞癌,小细胞肺癌、三阴乳腺癌、肝细胞癌  

Target disease:

Driver gene negative non-small cell lung cancer, urothelial carcinoma, esophageal cancer, nasopharyngeal carcinoma, melanoma, renal cell carcinoma, small cell lung cancer, triple-negative breast cancer, hepatocellular carcinoma, renal cell carcinoma, small cell lung cancer, triple-negative breast cancer, hepatocellular carcinoma

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

观察或评估真实世界中特瑞普利治疗中国晚期或者适用全身系统治疗的局晚期实体肿瘤患者(驱动基因阴性非小细胞肺癌,尿路上皮癌,食管癌,鼻咽癌,黑色素瘤,肾细胞癌,小细胞肺癌、三阴乳腺癌、肝细胞癌,肾细胞癌,小细胞肺癌、三阴乳腺癌、肝细胞癌)的有效性和安全性  

Objectives of Study:

Observe or evaluate the treatment of Chinese patients with advanced or locally advanced solid tumors eligible for systemic therapy with toripalil in the real world (driver gene-negative non-small cell lung cancer, urothelial carcinoma, esophageal cancer, nasopharyngeal carcinoma, melanoma, renal cell carcinoma, small cell lung cancer, triple-negative breast cancer, hepatocellular carcinoma, renal cell carcinoma) The efficacy and safety of small cell lung cancer, triple-negative breast cancer and hepatocellular carcinoma

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.经病理学或细胞学确诊为对应的实体肿瘤(驱动基因阴性非小细胞肺癌,尿路上皮癌,食管癌,鼻咽癌,黑色素瘤,肾细胞癌,小细胞肺癌、三阴乳腺癌、肝细胞癌);
2.基于TNM分期为晚期(TXNXM1),或者适用全身系统治疗的局晚期;
3.至少有一个可经CT或MRI评价的病灶;
4.至少完成3周期特瑞普利单抗单药和/或联合治疗的患者;
5.至少完成1次有效性评估(首次用药6-12周影像评估);
6.受试者自愿加入本研究,并签署知情同意书。

Inclusion criteria

1. Pathologically or cytologically confirmed as the corresponding solid tumor (driver gene-negative non-small cell lung cancer, urothelial carcinoma, esophageal cancer, nasopharyngeal carcinoma, melanoma, renal cell carcinoma, small cell lung cancer, triple-negative breast cancer, hepatocellular carcinoma); 2. Based on the TNM stage being advanced (TXNXM1), or the locally advanced stage applicable for systemic treatment; 3. There is at least one lesion that can be evaluated by CT or MRI; 4. Patients who have completed at least 3 cycles of toripalimab monotherapy and/or combination therapy; 5. At least one effectiveness assessment (imaging assessment 6 to 12 weeks after the first administration) has been completed; 6. The subjects voluntarily joined this study and signed the informed consent form.

排除标准:

1.5年内曾罹患其它恶性肿瘤,但是研究治愈的局限性肿瘤除外; 2.观察期间参加过其他临床试验的患者; 3.本研究为真实世界研究,无特殊排除标准;

Exclusion criteria:

1. Having suffered from other malignant tumors within the past five years, except for localized tumors that have been cured through research. 2. Patients who participated in other clinical trials during the observation period; 3. This study is a real-world one and there are no special exclusion criteria.

研究实施时间:

Study execute time:

From 2026-03-31 00:00:00 To 2030-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-03-31 00:00:00 To 2028-03-31 00:00:00

干预措施:

Interventions:

组别:

特瑞普利单抗试验组

样本量:

300

Group:

Toripalimab experimental group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

烟台毓璜顶医院 

单位级别:

三级甲等 

Institution
hospital:

Yantai Yuhuangding Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

滨州市人民医院 

单位级别:

三级甲等 

Institution
hospital:

Binzhou People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

威海市立医院 

单位级别:

三级甲等 

Institution
hospital:

Weihai Municipal Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

宁津县人民医院 

单位级别:

二级甲等 

Institution
hospital:

Ningjin County People's Hospital

Level of the institution:

Secondary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

济宁市兖州区人民医院 

单位级别:

三级医院 

Institution
hospital:

People's Hospital of Yanzhou District, Jining City

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

庆云县人民医院 

单位级别:

三级乙等 

Institution
hospital:

Qingyun County People's Hospital

Level of the institution:

Tertiary B

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

淄博市立医院 

单位级别:

三级乙等 

Institution
hospital:

Zibo Municipal Hospital

Level of the institution:

Tertiary B

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

临邑县人民医院 

单位级别:

三级乙等 

Institution
hospital:

Linyi County People's Hospital

Level of the institution:

Tertiary B

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

齐河县人民医院 

单位级别:

三级医院 

Institution
hospital:

Qihe County People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

兖矿新里程总医院 

单位级别:

三级甲等 

Institution
hospital:

Yankuang New Milestone General Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

邹平市人民医院 

单位级别:

二级甲等 

Institution
hospital:

Zouping People's Hospital

Level of the institution:

Secondary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

滨州市中心医院 

单位级别:

三级甲等 

Institution
hospital:

Binzhou Central Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

淄博市中心医院 

单位级别:

三级甲等 

Institution
hospital:

Zibo Central Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

海阳市人民医院 

单位级别:

二级甲等 

Institution
hospital:

Haiyang People's Hospital

Level of the institution:

Secondary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

聊城市茌平区人民医院 

单位级别:

二级甲等 

Institution
hospital:

People's Hospital of Chiping District, Liaocheng City

Level of the institution:

Secondary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

章丘人民医院 

单位级别:

三级乙等 

Institution
hospital:

Zhangqiu People's Hospital

Level of the institution:

Tertiary B

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

德州市第二人民医院 

单位级别:

三级医院 

Institution
hospital:

Dezhou Second People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

郓城县人民医院 

单位级别:

三级乙等 

Institution
hospital:

Yuncheng County People's Hospital

Level of the institution:

Tertiary B

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

东明县人民医院 

单位级别:

三级医院 

Institution
hospital:

Dongming County People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

金乡县人民医院 

单位级别:

三级乙等 

Institution
hospital:

Jinxiang County People's Hospital

Level of the institution:

Tertiary B

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

济宁新里程肿瘤医院 

单位级别:

三级甲等 

Institution
hospital:

Jining New Milestone Cancer Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

宁阳县第一人民医院 

单位级别:

三级乙等 

Institution
hospital:

The First People's Hospital of Ningyang County

Level of the institution:

Tertiary B

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

汶上县人民医院 

单位级别:

三级乙等 

Institution
hospital:

Wenshang County People's Hospital

Level of the institution:

Tertiary B

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

菏泽市立医院 

单位级别:

三级甲等 

Institution
hospital:

Heze Municipal Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

济宁市第一人民医院 

单位级别:

三级甲等 

Institution
hospital:

Jining First People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

淄博市第四人民医院 

单位级别:

三级医院 

Institution
hospital:

Zibo Fourth People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

曲阜市人民医院 

单位级别:

三级医院 

Institution
hospital:

Qufu People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

高唐县人民医院 

单位级别:

三级乙等 

Institution
hospital:

Gaotang County People's Hospital

Level of the institution:

Tertiary B

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

莱西第三人民医院 

单位级别:

二级甲等 

Institution
hospital:

Laixi Third People's Hospital

Level of the institution:

Secondary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

临清市人民医院 

单位级别:

三级乙等 

Institution
hospital:

Linqing People's Hospital

Level of the institution:

Tertiary B

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

德州市陵城区人民医院 

单位级别:

二级甲等 

Institution
hospital:

People's Hospital of Lingcheng District, Dezhou City

Level of the institution:

Secondary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

泰安市中心医院 

单位级别:

三级甲等 

Institution
hospital:

Tai 'an Central Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

曲阜市中医院 

单位级别:

三级甲等 

Institution
hospital:

Qufu Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

济宁医学院附属医院 

单位级别:

三级甲等 

Institution
hospital:

Affiliated Hospital of Jining Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

梁山县人民医院 

单位级别:

三级医院 

Institution
hospital:

Liangshan County People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

山东第一医科大学附属肿瘤第三医院 

单位级别:

三级甲等 

Institution
hospital:

The Third Affiliated Cancer Hospital of Shandong First Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

单县中心医院 

单位级别:

三级甲等 

Institution
hospital:

Shanxian Central Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

济宁市第一人民医院 

单位级别:

三级甲等 

Institution
hospital:

Jining First People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

聊城市人民医院 

单位级别:

三级甲等 

Institution
hospital:

Liaocheng People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

肥城市人民医院 

单位级别:

三级乙等 

Institution
hospital:

Feicheng People's Hospital

Level of the institution:

Tertiary B

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

潍坊市人民医院 

单位级别:

三级甲等 

Institution
hospital:

Weifang People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

总生存期

指标类型:

次要指标

Outcome:

Overall survival

Type:

Secondary indicator

测量时间点:

每6周评估

测量方法:

CT或MRI

Measure time point of outcome:

Evaluate every 6 weeks

Measure method:

CT or MRI

指标中文名:

无进展生存期

指标类型:

次要指标

Outcome:

Progression-free survival

Type:

Secondary indicator

测量时间点:

每6周评估

测量方法:

CT或MRI

Measure time point of outcome:

Evaluate every 6 weeks

Measure method:

CT or MRI

指标中文名:

客观缓解率

指标类型:

主要指标

Outcome:

Objective response rate

Type:

Primary indicator

测量时间点:

每6周评估

测量方法:

CT或MRI

Measure time point of outcome:

Evaluate every 6 weeks

Measure method:

CT or MRI

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历报告表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-03-31 14:26:51